, Columnist
Celgene Needs a Boost, But Juno Isn't It
Cell therapies are complicated and expensive, and rivals have a head start.
This article is for subscribers only.
Celgene Corp. apparently heard investor complaints about the paltry size of its last deal.
The Wall Street Journal reported Tuesday night that Celgene is hunting bigger game in Juno Therapeutics Inc. -- one of several companies developing so-called cell therapies, which use modified human immune cells to fight cancer.